Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | EPOR | P19235 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23334540 | 0.90 | TSHR (0.51) | TSHRHPGDSMN1; SMN2LMNAPKM | |
| SCHEMBL19155468 | 0.88 | TSHR (0.50) | TSHRHPGDSMN1; SMN2LMNAPKM | |
| SCHEMBL19069040 | 0.87 | TSHR (0.50) | TSHRHPGDSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL24433548 | 0.86 | TSHR (0.47) | TSHRHPGDSMN1; SMN2LMNAPKM | |
| SCHEMBL24253180 | 0.86 | TSHR (0.43) | TSHRHPGDLMNAPKMCNR1 | |
| SCHEMBL16134044 | 0.86 | TSHR (0.49) | TSHRHPGDSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL25028593 | 0.85 | TSHR (0.51) | TSHRHPGDSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL25649009 | 0.85 | TSHR (0.50) | TSHRHPGDSMN1; SMN2LMNAPKM | |
| SCHEMBL26866027 | 0.85 | GLP1R (0.41) | TSHRHPGDLMNAPKMCNR1 | |
| SCHEMBL26700881 | 0.84 | HPGD (0.45) | TSHRHPGDSMN1; SMN2LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714946-B2 | Bromodomain binding reagents and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20160033519-A1 | BROMODOMAIN BINDING REAGENTS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160033519-A1 | BROMODOMAIN BINDING REAGENTS AND USES THEREOF | BRD4, BRD1, BRDT | TSHR 1711/4885HPGD 3377/4885SMN1; SMN2 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.